Biogen Financials - Benzinga

Biogen Inc

BIIBNASDAQ

Trade with Public

Trade with Public

$230.13

2.531.11%

Dern. MÀJ: Sep 28, 12:33 PM

Aperçu Actualités Prévisions de résultats Événements Objectifs de coursDonnées financièresSentiment Actionnariat Comparer Options Rapport sur les stocks

Biogen Financials

Biogen (BIIB) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease Portfolio

Biogen beat second-quarter earnings and revenue estimates, raised its 2026 guidance, and reported pipeline progress.

Vandana Singh

PRO
CORRECTION: Biogen Raises FY2026 Adj EPS Guidance from $15.25-$16.25 to $15.85-$16.85 vs $12.83 Est

Biogen (NASDAQ:BIIB) raises FY2026 Adj EPS guidance from $15.25-$16.25 to $15.85-$16.85 vs $12.83 analyst estimate..

Benzinga Newsdesk

PRO
Biogen Q2 Adj. EPS $3.60 Beats $2.96 Estimate, Sales $2.736B Beat $2.458B Estimate

Benzinga Newsdesk

PRO
Biogen Expects $164M Q2 2026 And $290M-$320M Q3 2026 IPR&D And Milestone Charges, Impacting Earnings By $0.95 And $1.75–$1.95 Per Share, Respectively

Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the second quarter of 2026 will include acquired in-process research and development, upfront and milestone expense of approximately $164 million on a

Benzinga Newsdesk

Biogen Analysts Boost Their Forecasts Following Upbeat Q1 Earnings

Biogen (NASDAQ:BIIB) reported strong Q1 earnings, beating expectations. However, they cut their FY2026 EPS guidance. Analysts have mixed opinions on buying BIIB stock.

Avi Kapoor

Earnings Scheduled For April 29, 2026

Benzinga Insights

© 2026 Benzinga | All Rights Reserved